120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
线粒体靶向纳米药物递送系统用于癌症治疗的最新进展
Authors Huang L, Lei Y , Zheng P, Chen Q, Wang C, Ma J
Received 14 September 2025
Accepted for publication 10 January 2026
Published 2 February 2026 Volume 2026:21 567593
DOI https://doi.org/10.2147/IJN.S567593
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Kamakhya Prakash Misra
Li Huang,1,* Yujing Lei,2,* Piao Zheng,3 Qingshan Chen,4 Chenyang Wang,1 Jie Ma5
1Pharmaceutical Preparation Center, The First Hospital of Hunan University of Chinese Medicine, Changsha, People’s Republic of China; 2College of Medicine and Medical Technology, Changsha Cultural Creative and Arts Vocational College, Changsha, People’s Republic of China; 3Department of Discipline Development and Research Management, The Second Hospital of Hunan University of Chinese Medicine, Changsha, People’s Republic of China; 4The Department of Hepatobiliary Pancreatic Hernia Surgery, The First Hospital of Hunan University of Chinese Medicine, Changsha, People’s Republic of China; 5Department of Traditional Chinese Medicine, Hunan Institute for Drug Control, Changsha, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Li Huang, Email huanglily0101@hnucm.edu.cn
Abstract: Cancer remains a major disease that poses a serious threat to human health. Conventional treatments such as radiotherapy, chemotherapy, and surgery are limited by systemic toxicity and tumor recurrence, which hinder the achievement of highly efficient and specific therapy. The development of nanodrug delivery systems has provided new opportunities for cancer treatment. Utilizing mechanisms such as passive targeting (eg, the EPR effect) and active targeting (eg, peptide-based surface modification), these systems can precisely deliver drugs to tumor sites, thereby significantly reducing systemic toxicity. In recent years, research focus has shifted from tissue-level targeting to subcellular organelle targeting, particularly of mitochondria. Functioning as cellular power plants, mitochondria are deeply involved in tumor initiation, progression, and the regulation of apoptosis, making them important targets for cancer therapy. Based on the structural features of mitochondria and their dysfunctional role in cancer, this review systematically explores strategies for mitochondria-targeted nanodrug delivery and summarizes the latest research advances along with future directions in cancer treatment. A unique aspect of this review is its systematic integration of the design principles from mitochondrial substructure characteristics to multi-level targeting strategies, underscoring the innovative potential of nanocarriers in overcoming tumor drug resistance and enabling precise intervention. This work thereby provides a theoretical basis and novel insights for precision oncology.
Keywords: nano-drug delivery carriers, mitochondrial targeting, tumor microenvironment, responsive nanocarriers
1Pharmaceutical Preparation Center, The First Hospital of Hunan University of Chinese Medicine, Changsha, People’s Republic of China; 2College of Medicine and Medical Technology, Changsha Cultural Creative and Arts Vocational College, Changsha, People’s Republic of China; 3Department of Discipline Development and Research Management, The Second Hospital of Hunan University of Chinese Medicine, Changsha, People’s Republic of China; 4The Department of Hepatobiliary Pancreatic Hernia Surgery, The First Hospital of Hunan University of Chinese Medicine, Changsha, People’s Republic of China; 5Department of Traditional Chinese Medicine, Hunan Institute for Drug Control, Changsha, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Li Huang, Email huanglily0101@hnucm.edu.cn
Abstract: Cancer remains a major disease that poses a serious threat to human health. Conventional treatments such as radiotherapy, chemotherapy, and surgery are limited by systemic toxicity and tumor recurrence, which hinder the achievement of highly efficient and specific therapy. The development of nanodrug delivery systems has provided new opportunities for cancer treatment. Utilizing mechanisms such as passive targeting (eg, the EPR effect) and active targeting (eg, peptide-based surface modification), these systems can precisely deliver drugs to tumor sites, thereby significantly reducing systemic toxicity. In recent years, research focus has shifted from tissue-level targeting to subcellular organelle targeting, particularly of mitochondria. Functioning as cellular power plants, mitochondria are deeply involved in tumor initiation, progression, and the regulation of apoptosis, making them important targets for cancer therapy. Based on the structural features of mitochondria and their dysfunctional role in cancer, this review systematically explores strategies for mitochondria-targeted nanodrug delivery and summarizes the latest research advances along with future directions in cancer treatment. A unique aspect of this review is its systematic integration of the design principles from mitochondrial substructure characteristics to multi-level targeting strategies, underscoring the innovative potential of nanocarriers in overcoming tumor drug resistance and enabling precise intervention. This work thereby provides a theoretical basis and novel insights for precision oncology.
Keywords: nano-drug delivery carriers, mitochondrial targeting, tumor microenvironment, responsive nanocarriers